Roche is making a massive bet on the United States.
The Swiss pharmaceutical company announced that it will invest $50 billion across the United States over the next five years. The move comes as drugmakers around the world brace for possible new tariffs from the Trump administration, which recently launched a “national security” investigation into pharmaceutical imports.
Roche said the investment will create more than 12,000 jobs, including nearly 6,500 construction roles, and boost U.S. manufacturing, research, and distribution operations. The company plans to expand its existing sites in Kentucky, Indiana, New Jersey, Oregon, and California, while building new factories for gene therapy and glucose monitoring, as well as a research center in Massachusetts focused on cardiovascular and metabolic diseases.
“We are proud of our 110-year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property,…